Searching...
12 results for “clinical trials”
...these trials. We are we are doing multimodal interventions, we call it, which means we first analyze who that person is, what the need is, and then giving the supplements and then retesting another supplement on top of it to actually see if one medic
26:15 / 27:18
from transcript26:15 – 27:18
...trials. We are we are doing multimodal interventions, we call it, which means we first analyze who that person is, what the need is, and then giving the supplements and then retesting another supplement on top of it to actually see if one medication
26:46 / 28:02
from transcript26:46 – 28:02
in currently in clinical trials and that are being used in certain clinics. And there's been a bit of a, pushback, especially amongst the academic community who believe that there needs to be more rigorous data. As a clinician who runs a clinic, what
34:25 / 35:30
from transcript34:25 – 35:30
...pivotal trials for a drug to one pivotal trial for a drug. It's just math. You can achieve the same statistical power if you design one good clinical trial properly with a good control group.
13:29 / 14:30
from transcript13:29 – 14:30
So we've got to talk about the value of the microbiome. And I would not be surprised if we had the research on that instead of just the DEI stuff we talked about. Mhmm. And study the microbiome the same way we're funding the Wuhan lab to study corona
1:22:29 / 1:23:34
from transcript1:22:29 – 1:23:34
and but also balancing the risk as well? Yeah. We always say we wanna be cutting edge but not bleeding edge. Like, we don't wanna be the people who are at the very, you know, the very first people to do any therapies, you know, before we have some an
34:47 / 36:18
from transcript34:47 – 36:18
...in the more clinical studies. And also in industry and the pharmaceutical industry and biotech, they are building on these basic discoveries that were funded by the NIH.
8:55 / 10:05
from transcript8:55 – 10:05
...preprint. Secondly, if you are gonna do something like that, ask as a part of a clinical trial. If you're gonna be going through a potentially helpful, potentially harmful procedure, hopefully, that data being collected and build a knowledge set so t
1:03:03 / 1:04:00
from transcript1:03:03 – 1:04:00
...duration clinical trial is a product of scale. You're recruiting tons and tons of people. And the reason you're doing that is to get enough statistical significance that you can show the drug works or not. And that's because you don't know specifical
20:54 / 22:05
from transcript20:54 – 22:05
I was at the Montreal Neurological Institute. So I was hired as a young scientist by this company to just document what are the mechanism of action, what can we document scientifically to support any of the claims that they were making, to be in comp
3:41 / 4:49
from transcript3:41 – 4:49
...clinical trials go phase one, phase two, phase three. Phase one is efficacy. So phase one is safety, and then phase three is ultimately efficacy. This is now past everything. So this would really mean that, actually, this could be approved and on the
48:00 / 49:11
from transcript48:00 – 49:11
and cardiovascular disease because you'll be turning off their over cholesterol production. So that's moving ups ups upstream of the disease, and that's an exciting realm as well because most of the gene therapies, whether it's for health span or par
1:02:12 / 1:03:17
from transcript1:02:12 – 1:03:17
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.